CClinicalTrials.gg
CompletedNCT05411835Updated Apr 2, 2024

Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders

An Early Phase 1 interventional study of Nutritional Ketone Supplement and Isocaloric Placebo Supplement in Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Carnitine Palmitoyltransferase Deficiency 2 and Very Long Chain Acyl Coa Dehydrogenase Deficiency, sponsored by Oregon Health and Science University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by Oregon Health and Science University · Early Phase 1, Interventional, and Other

Phase
Early Phase 1
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to determine if an oral ketone beverage is safe and well-tolerated during moderate intensity exercise in participants with long-chain fatty acid oxidation disorders and if it will raise blood ketones to levels similar to that reported among normal healthy subjects.

Read the detailed description

Purpose: Subjects with long-chain fatty acid oxidation disorders (LC-FAOD) do not make ketones during fasting or with exercise. Ketones are an important alternative energy substrate during moderate exercise, sparing the oxidation of glucose and providing a source of ATP to the central nervous system and exercising muscle. Fatty acid oxidation in the liver is required to make ketones. Subjects with a LC-FAOD cannot generate ketones because of their block in fatty acid oxidation during exercise. Providing ketones in an oral ketone beverage may increase blood ketones with exercise to levels normally observed in humans.

Aim: To determine the safety and tolerability of an oral ketone beverage during moderate intensity exercise among subjects with a LC-FAOD compared to an isocaloric maltodextrin beverage, and to determine blood ketone concentrations.

Hypothesis: Oral consumption of a ketone beverage before moderate intensity exercise will be safe and well-tolerated, and will raise blood ketones among subjects with a LC-FAOD to concentrations similar to that reported in the literature among normal healthy subjects.

02

Conditions studied

  • Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
  • Carnitine Palmitoyltransferase Deficiency 2
  • Very Long Chain Acyl Coa Dehydrogenase Deficiency
  • Trifunctional Protein Deficiency

Browse trials for

03

In context

Protein Deficiency

26 studies on the registry are indexed under Protein Deficiency; 4 are open to participants now.

This study's enrollment of 5 is below the median of 40 across 20 interventional studies indexed under Protein Deficiency.

Browse Protein Deficiency studies →

Lead sponsor

Oregon Health and Science University is the lead sponsor of 676 studies on the registry; 136 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 36 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • confirmed diagnosis of VLCAD, LCHAD/TFP or CPT2 deficiency
  • speak English
  • willing to complete 2 moderate intensity exercise treadmills

Exclusion criteria

Exclusion Criteria:

  • subjects actively participating in another research study that prohibits their participation
  • pregnant females
  • subjects with diabetes or taking medications to treat diabetes
05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Active comparator
    Nutrition Ketogenic Supplement

    The Ketone pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains a mix of D-beta-hydroxybutyrate salts, flavors and stevia.

    Dietary Supplement: Nutritional Ketone Supplement

  • Sham comparator
    Isocaloric Placebo Supplement

    The maltodextrin pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains an isocaloric amount of maltodextrin, flavors and stevia similar to the ketone beverage.

    Dietary Supplement: Isocaloric Placebo Supplement

Interventions

  • Dietary supplementNutritional Ketone Supplement

    Mix of sodium, calcium, and magnesium salts of D-beta-hydroxybutyrate with nicotinamide riboside chloride, flavors and stevia sweetener

    Also known as: NKS

  • Dietary supplementIsocaloric Placebo Supplement

    Maltodextrin with flavors and stevia sweetener

06

What researchers measure

Primary outcomes

  1. Adverse Events- incidence

    Number of Adverse events

    Time frame: 2 hours after product intake

  2. Adverse Events- type

    Description of Adverse events: categorical

    Time frame: 2 hours after product intake

  3. Adverse Events- severity

    Severity of adverse event: grade 1-5

    Time frame: 2 hours after product intake

  4. Adverse Events- causal relationship

    Yes/No related to product intake

    Time frame: 2 hours after product intake

  5. Abdominal discomfort

    visual analogue scale (VAS) 0-10

    Time frame: 2 hours after product intake

  6. Decreased appetite

    visual analogue scale (VAS) 0-10

    Time frame: 2 hours after product intake

  7. Gastric reflux

    visual analogue scale (VAS) 0-10

    Time frame: 2 hours after product intake

  8. Nausea

    visual analogue scale (VAS) 0-10

    Time frame: 2 hours after product intake

  9. Diarrhea

    visual analogue scale (VAS) 0-10

    Time frame: 2 hours after product intake

  10. Headache

    visual analogue scale (VAS) 0-10

    Time frame: 2 hours after product intake

Secondary outcomes

  1. Blood Ketones

    plasma beta-hydroxybutyrate concentration

    Time frame: 20 minutes after moderate intensity exercise

  2. Blood Creatine Kinase

    plasma CK concentration

    Time frame: 20 minutes after moderate intensity exercise

  3. Blood Glucose

    serum glucose

    Time frame: 20 minutes after moderate intensity exercise

  4. Blood Lactate

    serum lactate concentration

    Time frame: 20 minutes after moderate intensity exercise

  5. Blood Pressure

    diastolic BP

    Time frame: peak 40 minute exercise

  6. Blood Pressure

    systolic BP

    Time frame: peak 40 minute exercise

  7. Perceived exertion

    Borg scale 1-20

    Time frame: peak 40 minute exercise

  8. Respiratory Exchange Ratio

    VCO2/VO2 0.7 - 1.0

    Time frame: peak 40 minute exercise

  9. Heart Rate

    beats per minute

    Time frame: peak 40 minute exercise

07

Study locations

1 site
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
08

References and documents

Individual participant data

Plan to share: Yes — Participants will be provided with creatine kinase lab test and body composition measurement. The results of their creatine kinase lab test will be placed in their medical record. Results of the study will be written in a published manuscript and summarized in a cover letter to be sent via mail or email to the participant after publication of the data.

Supporting information: Study protocol, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05411835
Lead sponsor
Oregon Health and Science University
Responsible party
Melanie B Gillingham (Associate Professor, Oregon Health and Science University) — Principal investigator
First posted
Jun 9, 2022
Start date
Aug 1, 2022
Primary completion
Jan 31, 2023
Completion
Jan 22, 2024
Last update
Apr 2, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion